We use cookies to offer you the best experience on our site. You can find out more about the cookies we use or disable them in the Cookie settings
Be sure to order on time
Eurogentec will be closed from 25th December 2024 until 1st January 2025.
Oligonucleotides
Custom ASO Manufacturing
With over 40 years of experience in oligonucleotide production, we offer tailored solutions for manufacturing custom antisense oligonucleotides (ASOs) that support the early stages of therapeutic development, particularly during the screening phase. Our expertise, state-of-the-art facilities, and commitment to quality allow us to guide our customers from discovery to clinical.
Custom ASO production capabilities
We efficiently produce ASO sequences ranging from 15 to 22 mers with a minimal delivered
quantity of 10 nmols per ASO, scaling up to larger batches as needed.
Our laboratories, equipped with state-of-the-art Shasta synthesizers, enable the parallel synthesis
of 5 to 200 oligonucleotides, with the capacity to support more extensive projects upon request.
| Specification | Details |
|---|---|
| Length | 15 to 22 mers |
| Quantity | Minimal delivery : 10 nmol/oligo From 5 to >1000 sequences |
| Chemistries and Modifications | LNA®, 2'O-Me, 2'O-MOE, 2’-Fluoro RNA, Phosphorothioate linkages |
| Purification | SePOP desalting by default; HPLC available |
| Quality Controls | Mass spectrometry + single quantification |
| Formats | Dried or in solution |
Key modifications for ASO screening
There are key modifications that ensure optimal performance in ASO screening. While some
modifications primarily enhance the stability of the ASO sequence, others are designed to improve
target binding and overall efficacy, facilitating more efficient screening and therapeutic
development while reducing potential off-target effects.
Phosphorothioate (PS)
PS links increase nuclease resistance, enhancing ASO stability in both in vitro and in vivo settings.
2'O-Me & 2′O-MOE bases
2'O-Me & 2′O-MOE bases enhance RNA affinity and protect against nuclease degradation in vitro and in vivo.
Locked Nucleic Acid (LNA®)
LNA® bases are highly useful in improving the efficacy and precision of ASOs targeting specific RNA sequences.
Gapmer Design
Gapmers are highly effective for silencing both nuclear and cytoplasmic RNA targets.
GalNAc
Improves ASO delivery to the liver by enhancing uptake through the asialoglycoprotein receptor.
PEGylation (PEG)
Extends ASO circulation by reducing renal clearance and improving bioavailability in vivo.
5′ and 3′ End Capping
Adding chemical caps to the 5′ or 3′ ends of ASOs helps to prevent degradation by exonucleases.
Bridged Nucleic Acids (BNA)
Improve resistance to nuclease degradation and enhance antisense activity.
Morpholino Oligomers (PMO)
Feature a non-ionic, enzyme-resistant backbone, offering enhanced therapeutic efficacy.
Formats to fit your application
Our expert chemists deliver antisense oligonucleotides in various formats to meet the specific requirements of your application. We offer flexible delivery options, ranging from individual tubes to 96-well plates. The oligonucleotides can be shipped either dried or in solution, facilitating seamless integration into your workflows and development processes.
Fast turnaround time production
Our qualified project managers, skilled scientists and robust manufacturing capabilities enable us to produce custom ASO sequences within a fast turnaround time. This efficiency allows our customers to accelerate their research and development timelines without compromising on quality.
Featured citations
Antisense Oligonucleotide-Mediated Downregulation of IGFBPs Enhances IGF-1 Signaling
Alper Yavas, Maaike van Putten and Annemieke Aartsma-Rus
Journal of Neuromuscular Diseases 11 (2024) 299–314 DOI 10.3233/JND-230118
All the ASOs used in the study were produced by Eurogentec
Preclinical Development of Antisense Oligonucleotides to Rescue Aberrant Splicing
Caused by an Ultrarare ABCA4 Variant in a Child with Early-Onset Stargardt Disease
Nuria Suárez-Herrera et.al.
Cells 2024 13(7) 601 DOI 10.3390/cells13070601
All the ASOs used in the study were produced by Eurogentec